ANNX

Annexon, Inc. [ANNX] Stock Forecast

Q: What is Annexon, Inc. stock symbol ?

Annexon, Inc. is a US stock, located in Brisbane of Ca and trading under the symbol ANNX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ANNX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 24.52%

ANNX has less than 1 year of cash runway

Top 10 Correlated ETFs

ANNX

Top 10 Correlated Stocks

ANNX

In the News

11:55 08 Jun 2023 ANNX

Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why

Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.

11:52 08 Jun 2023 ANNX

Why Shares of Annexon Are Plummeting Thursday

Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.

09:23 08 Jun 2023 ANNX

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.

07:47 08 Jun 2023 ANNX

May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but peak gains were in COIN +14.4% and TLRY +7.1%. The Active ETF portfolio continues with YTD gains at +14.2%.

08:01 08 Jun 2023 ANNX

April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge

April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge.

06:30 08 Jun 2023 ANNX

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.

12:29 08 Jun 2023 ANNX

Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues

Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain. The 28 patients were dosed for six months and followed for three more.

06:30 08 Jun 2023 ANNX

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.

07:30 08 Jun 2023 ANNX

Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings

BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings.

06:30 08 Jun 2023 ANNX

Annexon Biosciences to Participate in Upcoming May Investor Conferences

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:

ANNX Financial details

Company Rating

Neutral

Market Cap

158.19M

Income

-138.55M

Revenue

Book val./share

2.91

Cash/share

3.09

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 Aug 2023

P/E

-1.66

Forward P/E

PEG

0.56

P/S

P/B

1.07

P/C

0.95

P/FCF

-1.37

Quick Ratio

9.95

Current Ratio

10.14

Debt / Equity

0.25

LT Debt / Equity

0.14

EPS (TTM)

-2.38

EPS next Y

EPS next Q

EPS this Y

-25.37%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

9.09%

SMA20

-50%

SMA50

-25%

SMA100

-50%

Inst Own

98.7%

Inst Trans

28.06%

ROA

-52%

ROE

-63%

ROC

-0.62%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

53.08M

Shs Float

29.78M

Target Price

52W Range

2.07-7.65

52W High

-57.93%

52W Low

+47.25%

RSI

Rel Volume

1.83

Avg Volume

797.13K

Volume

1.46M

Perf Week

-1.17%

Perf Month

-45.96%

Perf Quarter

-47.03%

Perf Half Y

-48.78%

Beta

0.470865

Volatility

0.09%, 1.34%

Prev Close

-5.61%

Price

2.945

Change

-9.1%

ANNX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-1.6	-2.83	-3.7	-3.39	-2.53
Operating cash flow per share	-1.5	-2.16	-3.13	-2.77	-2.13
Free cash flow per share	-1.5	-2.18	-3.16	-2.81	-2.25
Cash per share	3.86	3.35	20.7	6.33	4.44
Book value per share	3.31	3.32	20.3	6.05	4.23
Tangible book value per share	3.31	3.32	20.3	6.05	4.23
Share holders equity per share	3.31	3.32	20.3	6.05	4.23
Interest debt per share	0	0.36	0	0.85	0.67
Market cap	203.39M	232.98M	424.57M	440.25M	282.66M
Enterprise value	159.22M	189.04M	156M	400M	175.5M
P/E ratio	-11.11	-6.27	-6.77	-3.39	-2.04
Price to sales ratio	0	0	0	0	0
POCF ratio	-11.83	-8.22	-8	-4.15	-2.43
PFCF ratio	-11.82	-8.14	-7.93	-4.09	-2.3
P/B Ratio	5.37	5.35	1.23	1.9	1.22
PTB ratio	5.37	5.35	1.23	1.9	1.22
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-8.94	-5.9	-2.46	-3.06	-1.21
EV to operating cash flow	-9.26	-6.67	-2.94	-3.77	-1.51
EV to free cash flow	-9.25	-6.6	-2.91	-3.71	-1.43
Earnings yield	-0.09	-0.16	-0.15	-0.3	-0.49
Free cash flow yield	-0.08	-0.12	-0.13	-0.24	-0.43
Debt to equity	0.27	0.15	0.03	0.24	0.23
Debt to assets	0.21	0.13	0.03	0.19	0.19
Net debt to EBITDA	2.48	1.37	4.23	0.31	0.74
Current ratio	13.74	9.21	33.33	11.39	11.1
Interest coverage	0	-6.98	0	61.05	-39.87
Income quality	0.94	0.76	0.84	0.81	0.82
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0.01	0.02	0.06
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.03	-0.54	-0.7	-0.77	-3.1
Stock based compensation to revenue	0	0	0	0	0
Graham number	10.91	14.55	41.08	21.49	15.51
ROIC	0.46	0.81	0.34	-1.03	60.11
Return on tangible assets	-0.38	-0.75	-0.18	-0.45	-0.49
Graham Net	2.98	2.87	20.02	4.9	3.45
Working capital	42.38M	40.48M	343.39M	225.95M	225.74M
Tangible asset value	37.88M	43.53M	344.28M	231.91M	231.19M
Net current asset value	35.44M	39.04M	342.34M	192.56M	194.2M
Invested capital	0	0	0	0.15	0.14
Average receivables	0	152K	41K	1.5K	0
Average payables	0	1.82M	3.05M	7.44M	9.28M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.48	-0.85	-0.18	-0.56	-0.6
Capex per share	0	-0.02	-0.03	-0.04	-0.12

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	0	0	0	0	0
Net income per share	-0.92	-0.96	-0.5	-0.44	-0.48
Operating cash flow per share	-0.79	-0.73	-0.45	-0.38	-0.45
Free cash flow per share	-0.92	-0.75	-0.45	-0.38	-0.45
Cash per share	5.36	4.6	3.93	3.35	3.09
Book value per share	5.2	4.36	3.8	3.19	2.91
Tangible book value per share	5.2	4.36	3.8	3.19	2.91
Share holders equity per share	5.2	4.36	3.8	3.19	2.91
Interest debt per share	0.89	0.89	0.51	0.49	0.4
Market cap	105.28M	145.46M	424.27M	374.15M	284.34M
Enterprise value	26.63M	74.98M	247.32M	266.98M	172.73M
P/E ratio	-0.75	-0.99	-3.12	-2.92	-2
Price to sales ratio	0	0	0	0	0
POCF ratio	-3.48	-5.16	-13.81	-13.79	-8.62
PFCF ratio	-2.97	-5.01	-13.74	-13.64	-8.58
P/B Ratio	0.52	0.87	1.63	1.62	1.32
PTB ratio	0.52	0.87	1.63	1.62	1.32
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-0.76	-2.03	-6.96	-7.28	-4.19
EV to operating cash flow	-0.88	-2.66	-8.05	-9.84	-5.24
EV to free cash flow	-0.75	-2.58	-8.01	-9.74	-5.21
Earnings yield	-0.34	-0.25	-0.08	-0.09	-0.13
Free cash flow yield	-0.34	-0.2	-0.07	-0.07	-0.12
Debt to equity	0.25	0.31	0.2	0.23	0.25
Debt to assets	0.2	0.24	0.17	0.19	0.2
Net debt to EBITDA	2.25	1.91	4.98	2.92	2.71
Current ratio	12.39	8.95	13.59	11.1	10.14
Interest coverage	-668.42	-137.53	-35.54	-15.87	13.3
Income quality	0.86	0.76	0.88	0.79	0.85
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.17	0.03	0.01	0.01	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-10.07	-1.59	-0.33	-0.53	-0.26
Stock based compensation to revenue	0	0	0	0	0
Graham number	10.35	9.68	6.51	5.64	5.62
ROIC	-2.28	-31.6	0.3	14.5	1.27
Return on tangible assets	-0.14	-0.17	-0.11	-0.11	-0.13
Graham Net	4.06	3.24	3.17	2.61	2.36
Working capital	194.2M	161.12M	254.56M	225.74M	209.6M
Tangible asset value	200.61M	168.04M	260.6M	231.19M	214.86M
Net current asset value	161.3M	128.71M	222.66M	194.2M	178.62M
Invested capital	0.17	0.2	0.13	0.14	0.15
Average receivables	0	0	0	0	0
Average payables	10.27M	9.84M	8.61M	7.17M	8.88M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.18	-0.22	-0.13	-0.14	-0.17
Capex per share	-0.14	-0.02	0	0	0

ANNX Frequently Asked Questions

What is Annexon, Inc. stock symbol ?

Annexon, Inc. is a US stock , located in Brisbane of Ca and trading under the symbol ANNX

What is Annexon, Inc. stock quote today ?

Annexon, Inc. stock price is $2.945 today.

Is Annexon, Inc. stock public?

Yes, Annexon, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 797.13K
Market Capitalization 158.19M
Employee 80
CEO Mr. Douglas Love Esq., J.D.
Headquarters Brisbane,CA,US
IPO Date 2020-07-24
Website https://www.annexonbio.com

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.